Drugs / Delpazolid
Delpazolid
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT03492996 | Jun → Aug 2020 | — | LigaChem Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02882789 | Sep 2016 → Jul 2017 | — | LigaChem Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02538003 | Sep → Dec 2015 | — | LigaChem Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02529241 | Jul → Dec 2015 | — | LigaChem Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02540460 | Jun → Dec 2014 | — | LigaChem Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01842516 | Mar → Jul 2013 | — | LigaChem Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01554995 | Mar → Dec 2012 | — | LigaChem Biosciences, Inc. | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT06004037 | Jan 2024 → Sep 2025 | pulmonary non-tuberculous mycobacterial infection | LigaChem Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06114628 | Jan 2024 → Feb 2027 expected | pulmonary tuberculosis | University College, London | Recruiting | No outcome recorded |
| Phase 2 | NCT05807399 | Apr 2023 → Oct 2027 expected | pulmonary tuberculosis | Michael Hoelscher | Recruiting | No outcome recorded |
| Phase 2 | NCT05225558 | Apr 2022 → Feb 2024 | staphylococcal infection | LigaChem Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04550832 | Oct 2021 → Jan 2023 | pulmonary tuberculosis | LigaChem Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02836483 | Dec 2016 → Jul 2019 | pulmonary tuberculosis | LigaChem Biosciences, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07675954 | Oct 2026 → Jun 2032 expected | rifampicin-resistant tuberculosis | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Delpazolid | “Delpazolid (LCB01-0371) is a novel oxazolidinone derivative with a good safety profile for treating gram-positive pathogenic infections such as Mycobacterium abscessus, a...” PMID 38436463 ↗ Mar 20246“The investigational MDR-END Plus regimen consists of oral anti-tuberculosis drugs including bedaquiline, delamanid, delpazolid, levofloxacin, and pyrazinamide.” NCT07675954 ↗ |
| Known as | DZD | “Drug: Delpazolid (DZD)” NCT06114628 ↗ |
| Known as | LCB01-0371 | “Delpazolid (LCB01-0371)” NCT05807399 ↗ |
| Modality | Small molecule | “LCB01-0371 is a novel oxazolidinone with broad-spectrum activity against Gram-positive pathogens in both in vitro studies and animal infection models.” PMID 29712654 ↗ Jun 2018 |
| Route | Oral | “multiple oral dosing of LCB01-0371 (200-mg tablet or 400-mg tablet) for 7 days” PMID 30420289 ↗ Nov 2018 |